晚期非小细胞肺癌的免疫及靶向治疗新进展科目讲解.pptVIP

晚期NSCLC免疫和靶向治疗新进展;主要内容;主要内容;The hallmarks of cancer. Cell. 2000;肿瘤免疫和免疫逃逸机制;Balance of immunostimulation and immunosuppression in tumor immunology;NSCLC免疫治疗方法—免疫检查点抑制剂;肺癌主动免疫治疗;主要内容;Ipilimumab;Ipilimumab：作用机理;近年来临床研究中治疗肺癌明确有效的单抗 1. Ipilimumab Now being tested in phase III trials for NSCLC and for SCLC .? Other open ipilimumab trials include: A phase II trial of ipilimumab plus chemotherapy before surgery for patients with NSCLC. A phase I trial of ipilimumab plus targeted therapies (erlotinib or crizotinib) for patients with stage IV NSCLC who also have EGFR or ALK mutations. A phase I tri